Study Announcements

NN107 FX-LEARN is now enrolling

Study subject enrollment has commenced at several sites which have achieved site approval by the NeuroNEXT Clinical Coordination Center.  Additional study sites are progressing through the site approval process, and will begin enrolling study subjects soon.

NN107 Fragile X Grant Release

Rush University Medical Center Awarded $11.5 Million for Fragile X Research
Promising New Drug Therapy for Language Learning

NN103 BeatMG trial achieves enrollment goal

The NN103 BeatMG Study Team is pleased to announce that the study has reached its goal of 50 randomized participants as of April 19th, 2016!  Please click here for official

NN102 SPRINT MS Patient Webinar

Please find the NN102 SPRINT MS Patient webinar posted below. For more information about this study, or if you have any questions, please contact Michelle McGovern (MMCCOURT1@mgh.harvard.edu) or Akshata Ashokkummar (AASHOKKUMAR@PARTNERS.ORG).

Patient Webinar

NN101 SMA Biomarker Principal Investigator speaks at Cure SMA 2015 Researcher meeting

Please see this article describing a talk at the Cure SMA 2015 Researcher meeting related to the NN101 SMA Biomarker study.  Speaking on initial results was Stephen Kolb, MD, from The Ohio State University.  He is the principal investigator for the study.

Pages